{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:54:26Z","timestamp":1791550466276,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"DOI":"10.1007\/s00120-026-02939-9","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:23:25Z","timestamp":1791548605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Belzutifan in der Behandlung des Nierenzellkarzinoms","Belzutifan in the treatment of renal cell carcinoma"],"prefix":"10.1007","author":[{"given":"Thomas","family":"B\u00fcttner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"9637","key":"2939_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer\u00a0RJ, Escudier\u00a0B, Oudard\u00a0S et\u00a0al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet 372(9637):449\u2013456. https:\/\/doi.org\/10.1016\/S0140-6736(08)61039-9","journal-title":"The Lancet"},{"issue":"19","key":"2939_CR2","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri\u00a0TK, Escudier\u00a0B, Powles\u00a0T et\u00a0al (2015) Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine 373(19):1814\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1510016","journal-title":"New England Journal of Medicine"},{"issue":"10407","key":"2939_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(23)00913-3","volume":"402","author":"CW Ryan","year":"2023","unstructured":"Ryan\u00a0CW, Tangen\u00a0CM, Heath\u00a0EI et\u00a0al (2023) Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet 402(10407):1043\u20131051. https:\/\/doi.org\/10.1016\/S0140-6736(23)00913-3","journal-title":"The Lancet"},{"issue":"8","key":"2939_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri\u00a0TK, Powles\u00a0T, Peltola\u00a0K et\u00a0al (2024) Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. New England Journal of Medicine 391(8):710\u2013721. https:\/\/doi.org\/10.1056\/NEJMoa2313906","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"2939_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri\u00a0TK, Bauer\u00a0TM, Papadopoulos\u00a0KP et\u00a0al (2021) Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a\u00a0phase\u00a01\u00a0trial and biomarker analysis. Nat Med 27(5):802\u2013805. https:\/\/doi.org\/10.1038\/s41591-021-01324-7","journal-title":"Nature Medicine"},{"key":"2939_CR6","unstructured":"Belzutifan. Fachinformation. Accessed 01.05.2026, https:\/\/www.fachinfo.de\/fi\/detail\/025232"},{"issue":"22","key":"2939_CR7","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch\u00a0E, Donskov\u00a0F, Iliopoulos\u00a0O et\u00a0al (2021) Belzutifan for Renal Cell Carcinoma in von Hippel\u2013Lindau Disease. New England Journal of Medicine 385(22):2036\u20132046. https:\/\/doi.org\/10.1056\/NEJMoa2103425","journal-title":"New England Journal of Medicine"},{"issue":"16_suppl","key":"2939_CR8","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1200\/JCO.2026.44.16_suppl.4550","volume":"44","author":"R Srinivasan","year":"2026","unstructured":"Srinivasan\u00a0R, Narayan\u00a0V, Iliopoulos\u00a0O et\u00a0al (2026) Extended follow-up (6\u00a0years) of the phase\u00a02 LITESPARK-004 study of belzutifan in participants with von Hippel-Lindau disease\u2013associated neoplasms. J\u00a0Clin Oncol 44(16_suppl):4550\u20134550. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.4550","journal-title":"Journal of Clinical Oncology"},{"issue":"7_suppl","key":"2939_CR9","doi-asserted-by":"publisher","first-page":"LBA417","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA417","volume":"44","author":"RJ Motzer","year":"2026","unstructured":"Motzer\u00a0RJ, Park\u00a0SH, McDermott\u00a0RS et\u00a0al (2026) Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti\u2013PD-(L)1\u00a0therapy: Open-label phase\u00a03 LITESPARK-011 study. J\u00a0Clin Oncol 44(7_suppl):LBA417\u2013LBA417. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.LBA417","journal-title":"Journal of Clinical Oncology"},{"issue":"7_suppl","key":"2939_CR10","doi-asserted-by":"publisher","first-page":"LBA418","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA418","volume":"44","author":"TK Choueiri","year":"2026","unstructured":"Choueiri\u00a0TK, Motzer\u00a0RJ, Karam\u00a0JA et\u00a0al (2026) Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study. J\u00a0Clin Oncol 44(7_suppl):LBA418\u2013LBA418. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.LBA418","journal-title":"Journal of Clinical Oncology"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02939-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:23:26Z","timestamp":1791548606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02939-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":10,"alternative-id":["2939"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02939-9","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0B\u00fcttner\n                      : A.\u00a0Finanzielle Interessen: Honorare von Astellas, Bayer, Medac; Kostenerstattung von Ipsen, MSD \u2013\u00a0Beraterrollen f\u00fcr Merck, Johnson&Johnson. B.\u00a0Nichtfinanzielle Interessen: Angestellter Urologe an der Klinik und Poliklinik f\u00fcr Urologie und Kinderurologie, Universit\u00e4tsklinikum Bonn | Mitgliedschaften: NRWGU, DGU, EAU, ESMO, BRIDGE e.\u202fV.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}